Project Grant R01HL174676
Award Date
8/12/24
Completion Date
5/31/29
Dollars Obligated
$1.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This federal Project Grant award, in the amount of $1,453,222.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports a multi-year research project to identify patient, clinician, health system, and societal factors contributing to inadequate and delayed screening for primary aldosteronism (PA), a common cause of secondary hypertension. The project aims to establish current patterns of PA...
This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $727,972 to investigate racial/ethnic disparities in hypertension treatment guideline concordance and blood pressure control in the Southeastern U.S. The research aims to 1) evaluate the extent of racial disparities in hypertension treatment per the 2017 AHA/ACC guidelines, 2) identify patient, provider, clinic, and geographic factors...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $246,776 to develop novel methods for creating and validating polygenic scores to predict medication response in African American populations with common chronic diseases. The award period runs from August 15, 2024 to July 31, 2026. The key objectives are to create ancestry-robust polygenic scores for African Americans that can predict...
This $1,092,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at the Medical College of Wisconsin, Inc. (MCW) to elucidate the molecular and physiological mechanisms controlling vascular function, arterial stiffness, and blood pressure regulation at the intersection of the renin-angiotensin system and the PPARG-RHOBTB1-CULLIN-3 pathways. The 7-year research program aims to...
This $477,134 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to define the mechanisms regulating the function of a novel cardiac protein called HERG1NP and its role in cardiac physiology and human disease. The key objectives are to: Identify the HERG1NP polypeptide and define the mechanisms regulating its biogenesis and activity in cardiac tissues. Determine how HERG1NP regulates...
This Project Grant award in the amount of $699,133 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to advance the understanding of heart failure with preserved ejection fraction (HFPEF), a condition affecting approximately 3 million Americans. The research will map the epigenomic and transcriptomic regulatory landscape across multiple organs, including the heart, kidney, and liver, to investigate the molecular...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year Project Grant totaling $717,236 to the University of Iowa on December 15, 2024 under the Cardiovascular Diseases Research program (CFDA 93.837). The goal of this research is to study the role of neuronal primary cilia in hypertension, autonomic dysfunction, and body fluid imbalance. The project aims to evaluate how conditional ablation of cilia in the supraoptic nucleus affects blood pressure, drinking, urine volume, sodium...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $267,310 to The Trustees of the University of Pennsylvania to investigate ancestry-specific genetic variations associated with heart, lung, blood, and sleep (HLBS) disorders. The key objectives are to: Curate a list of African American-specific predicted loss-of-function and missense genetic variants, and then characterize the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of progranulin, an anti-inflammatory protein, in regulating endothelial function and blood pressure control. The $1,568,003 award, made on September 3, 2024, aims to determine if reduced endothelial progranulin levels contribute to the development and progression of hypertension through oxidative stress, AMPK oxidation, and...
This Project Grant award, valued at $641,960 and awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research to investigate the mechanisms by which HIV-associated proteins contribute to the development of hypertension and cardiovascular disease in people with HIV. The Augusta University Research Institute, Inc., doing business as Georgia Health Sciences, will conduct this research over a 4-year...